Thymagen vs 5-Amino-1MQ
Side-by-side comparison of key properties, dosing, and research.
Immune Support
ThymagenFat Loss & Metabolic
5-Amino-1MQ- Summary
- Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Estimated 4–8 hours
- Admin Route
- SubQ, Oral
- Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 50–100 mg
- Frequency
- Daily for 10–30 days
- Once to twice daily
- Key Benefits
- Supports thymic epithelial cell function and T-cell maturation
- May partially restore thymic output reduced by age-related atrophy
- Normalizes T-lymphocyte subpopulation balance
- Supports immune recovery after illness, surgery, or chemotherapy
- Anti-aging effects on thymic tissue
- Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
- May improve vaccine responsiveness in older individuals
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant immunological adverse events reported
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Stacks With
- —
- —